--- a
+++ b/clusters/3009knumclusters/clust_16.txt
@@ -0,0 +1,961 @@
+Hemoglobin >= 9 g/dL, patients may receive transfusion to meet criterion within 30 days of day 1 of study
+Must be obtained within 14 days prior to registration for protocol therapy: Hemoglobin >= 8.5 g/dL
+Hemoglobin >= 10.0 g/dL and no blood transfusions in the 28 days prior to entry/randomization
+Within 14 days of treatment initiation: Hemoglobin >= 9 g/dL OR >= 5.6 mmol/L
+Hemoglobin ? 10 g/dL with no blood transfusions (packed red blood cells and platelet transfusions) in the past 28 days, within 28 days prior to administration of study treatment
+* Hemoglobin >= 8.0 g/dL at baseline (may receive red blood cell [RBC] transfusions)
+Hemoglobin >= 9 g/dL within 28 days prior to registration
+Within 28 days prior to registration: Hemoglobin >= 8 g/dL
+Hemoglobin >= 10 g/dL within 21 days prior to registration; patients must not have had a blood transfusion within 28 days prior to registration
+Hemoglobin >= 9 g/dL obtained within 28 days prior to sub-study registration
+Hemoglobin > 9 g/dL, obtained within 4 weeks prior to randomization
+Hemoglobin >= 9 g/dL must be obtained =< 7 days prior to protocol registration
+Hemoglobin >= 8 g/dL within 28 days prior to registration
+Hemoglobin >= 10.0 g/dL measured within 28 days prior to randomization
+Within less than or equal to 14 days prior to registration: Hemoglobin >= 10 g/dL
+Within 14 days of registration: Hemoglobin >= 10 g/dL
+Hemoglobin >= 9.0 g/L within 4 weeks before randomization
+Obtained within 28 days prior randomization: hemoglobin must be >= 8 g/dL
+Hemoglobin >= 10.0 g/dL (may receive red blood cell [RBC] transfusions)
+Obtained within 28 days prior to registration: Hemoglobin >= 8 g/dL
+Hemoglobin >= 9.0 g/dL, independent of transfusion and/or growth factors within 90 days prior to Step 1 registration
+Hemoglobin >= 10.0 g/dL and no known active bleeding, measured within 28 days prior to administration of study treatment
+Within 10 days of treatment initiation: Hemoglobin >= 8 g/dL
+Phase I only: Patients must have mean hemoglobin concentration < 10.0 g/dL of 2 measurements (not influenced by RBC transfusion within 7 days of measurement) and having received < 4 units of RBCs within 8 weeks prior to start of treatment OR,
+Preoperative hemoglobin concentration >= 10 mg/dL within 30 days of registration
+Hemoglobin >= 10 gm/dl; eligibility level for hemoglobin may be reached by transfusion
+Hemoglobin (Hgb) greater than 8.0 g/dL (may have packed red blood cell [PRBC] transfusion)
+Hemoglobin >= 8g/dl (unsupported)
+Hemoglobin >= 8 g/dL (blood transfusions are permitted for patients with hemoglobin levels below 8 g/dL) (within 14 days of treatment initiation)
+Measured within 28 days prior to registration: hemoglobin >= 10.0 g/dL with no blood transfusions (packed red blood cells in the past 28 days is permitted)
+Obtained =< 21 days prior to registration: Hemoglobin (Hgb) >= 9.0 g/dL NOTE: Subjects may not have had a transfusion =< 7 days of registration
+Hemoglobin (Hg) > 9 g/dL (=< 28 days prior to registration)
+Total hemoglobin >= 9 g/dL (may be post-transfusion)
+Within 14 days of treatment initiation: Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)
+Hemoglobin >= 9 g/dL (may have been transfused)
+Hemoglobin > 9 g/dL, transfusion permitted
+Pre-transfusion hemoglobin of <= 10 g/dL,
+Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment) (up to 14 days before treatment initiation)
+Hemoglobin > 8 g/dL (prior red blood cell [RBC] transfusion allowed); patients may be transfused to achieve this value
+Hemoglobin >= 9.0 g/dL must be met within 28 days of C1D1
+Obtained =< 14 days prior to registration: Hemoglobin >= 9.0 g/dL
+Hemoglobin >= 8.0 g/dL (may receive red blood cell [RBC] transfusions)
+Hemoglobin >= 10 gm/dL (transfusion is allowed to reach minimum level)
+Within 14 days of treatment initiation:\r\nHemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)
+Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)
+Within 10 days of treatment initiation: Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)
+Hemoglobin (Hb)A1c =< 7.0%
+Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment), performed within 10 days of treatment initiation
+Hemoglobin >= 9 g/dL or >= 5.6 mmol/L (without transfusion or growth factor support/erythropoietin [EPO] dependency)
+Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)
+Total hemoglobin >= 9 g/dL (which may be post transfusion)
+Hemoglobin >= 9 g/dL, within 14 days of registration
+Hemoglobin >= 8.0 g/dL (may be supported by erythropoietin) AND
+Hemoglobin levels at the time of or within 7 days prior to transfusions must have been ? 9.0 g/dL for the transfusions to qualify as required for the purpose of providing evidence of transfusion-dependent anemia.
+SAFETY RUN-IN: Within 10 days of registration: Hemoglobin >= 9 g/dL or >= 5.6 mmol/L
+RANDOMIZED PHASE II CLINICAL TRIAL: Within 10 days of registration: Hemoglobin >= 9 g/dL or >= 5.6 mmol/L
+Hemoglobin ? 8mg/dL (transfusion to reach this level is permitted)
+Hemoglobin (Hb) > 9 g/dL within 3 weeks prior to study registration
+Within 30 days prior to enrollment: Hemoglobin > 11 gm/dl
+Hemoglobin >= 9 gm/dl, performed within 14 days of treatment initiation
+Hemoglobin concentration >= 8 g/dL (may be transfused)
+Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)
+Hemoglobin (Hgb) >= 10 g/dL (may be achieved with erythropoietin agents; no blood transfusions in the 28 days prior to entry)
+Hemoglobin < 9 g/dL (< 5.5 mmol/L; previous red blood cell [RBC] transfusion is permitted).
+Hemoglobin ?9.0 g/dL without transfusion within the 2 weeks prior to Day 1.
+Hemoglobin >= 8.0 g/dl (without transfusion within the previous 7 days)
+Hemoglobin >= 9 g/dL, within 14 days before the first dose of cabozantinib
+Hemoglobin >= 9.0 gr/dL
+Hemoglobin >= 8 g/dL (80 g/L) within 14 days prior cycle 1, day 1 (subjects may be receiving red blood cell [RBC] transfusions in accordance with institutional guidelines)
+Hemoglobin >= 9 g/dl (patients may be transfused to this level)
+Hemoglobin >= 8.5 g/dl (recommended cutoff subject to judgment of medical oncologist), but cannot be transfusion dependent
+Hemoglobin >= 8.0 gm/dL; transfusion permitted to achieve this level
+Hemoglobin >= 9.0 gm/dL (may receive RBC transfusions)
+Hematocrit <30 percent or Hemoglobin < 10 g/dL
+Hemoglobin >= 9 g/dL within 7 days before the first dose of cabozantinib
+Have a hemoglobin ?9.0 g/dL without red blood cell transfusion for ?1 month.
+Hemoglobin < 9 g/dL (hemoglobin may be supported by transfusion, erythropoietin, or other approved hematopoietic growth factors)
+Within 10 (except as noted) days of planned treatment initiation: Hemoglobin >= 9.0 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin dependency (within 7 days of assessment)
+Hemoglobin >= 8 g/dL\r\n* Note: Patients may receive erythrocyte transfusions to achieve this hemoglobin level at the discretion of the investigator; initial treatment must not begin earlier
+Hemoglobin >= 9 g/dL (transfusion is acceptable to meet this criteria) within 28 days of treatment initiation and must be independent of hematopoietic growth factor support
+Obtained within 14 days prior to C1D1: Hemoglobin > 9.0 g/dL
+Hemoglobin ?9.0 grams per deciliter (g/dL);
+Hemoglobin (Hb) concentration < 8.0 g/dL
+Hemoglobin ?9 grams per deciliter (g/dL)
+ENROLLMENT TO THE DOSE ESCALATION, EXPANSION AND PART II: Hemoglobin >= 9 g/dL
+Obtained =< 2 weeks prior to registration: Hemoglobin >= 9 g/dL
+Obtained within 28 days prior to registration: Hemoglobin (Hgb) >= 9 g/dL (without erythrocyte stimulating agent or transfusion within 7 days of screening)
+Hemoglobin >= 9 g/dL performed within 30 days prior to the date of registration; no transfusions and erythropoietin supplementation permitted within the last 3 months
+Hemoglobin >= 9 g/dL or >= 5.6 mmol/L, performed within 10 days of treatment initiation, without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)
+Within 14 days of treatment registration: Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)
+Hemoglobin < 10.0 g/dL, independent of transfusion or growth factor support
+Obtained within 14 days prior to registration: Hemoglobin >= 10 g/dL
+Hemoglobin >= 9 g/dL (with or without transfusion support)
+Hemoglobin >= 8.0 g/dl (may be transfused) within 14 days of enrollment to trial
+Hemoglobin ?8 g/dL (?80 g/L) (superficial tumor dosing only)
+Hemoglobin >= 10 g/dL, completed within 14 days prior to the date of registration
+hemoglobin ? 9 g/dL; subjects requiring transfusion will be eligible to start study
+Hemoglobin >= 8.0 g/dL at baseline (may receive red blood cell [RBC] transfusions)
+Hemoglobin >= 8.0 g/dL at baseline (may receive red blood cell [RBC] transfusions)
+Hemoglobin >= 9 gm/dL before starting therapy; eligibility level for hemoglobin may be reached by transfusion
+Hemoglobin ? 9.0 g/dL independent of transfusion and/or growth factors within 3 months prior to randomization
+Hemoglobin >= 8 g/dL (with or without packed red blood cell [PRBC] transfusion) and documented within 14 days prior to registration and within 14 days prior to the start of treatment
+Documented within 14 days of registration: Hemoglobin >= 8 g/dL (may be supported)
+Hemoglobin greater than 9.0 mg/dl (transfusions are permitted to achieve baseline hemoglobin level), within 14 days prior to registration
+Hemoglobin >= 8.0 g/dL at least 3 weeks prior to screening unless attributable to disease
+Absolute neutrophil count (ANC) <1,500/mm3, pre-transfusion platelets <100,000/mm3, or pre-transfusion hemoglobin <9.0 mg/dL (the patient is required to have at least 2 weeks free from blood transfusion, G-CSF and erythropoietin use prior to the hematology test)
+Within 28 days of study registration: Hemoglobin >= 8 g/dL
+Hemoglobin >= 9 g/dL (with or without transfusion support)
+Obtained =< 35 days prior to registration: hemoglobin >= 8.0g/dL
+Hemoglobin ? 9 g/dL within 28 days prior to registration
+Hemoglobin >= 9 g/dL (with or without transfusion support) within 14 days prior to start of protocol therapy.
+Hemoglobin >8.0 mg/dL without red blood cell transfusion ? 3 days prior to C1D1
+Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment), performed within 14 days of treatment initiation
+Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment) within 14 days of treatment initiation
+Hemoglobin >= 8.0 g/dL (may receive transfusions)
+Hemoglobin >= 9.0 g/dL (with or without red blood cell [RBC] transfusion)
+Hemoglobin >= 8 g/dL (performed within 14 days of treatment initiation)
+Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment) (performed within 28 days of treatment initiation)
+Hemoglobin ?8 g/dL, with no red blood cell (RBC) transfusions within the prior 14 days.
+Hemoglobin < 9 g/dL (< 5.5 mmol/L; previous red blood cell transfusion is permitted)
+Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment), performed within 28 days of study registration
+Hemoglobin A1c < 7%
+Hemoglobin >= 8.0 g/dL, obtained =< 14 days prior to registration
+Within 14 days prior to registration: Hemoglobin >= 10 g/dL; patients may be transfused packed red blood cells (PRBCs) up to 1 week prior to when enrollment labs are drawn; on study, transfusions may be given as clinically indicated
+PHASE I: Hemoglobin >= 9 gm/dL
+PHASE IB: Hemoglobin >= 9 gm/dL
+Hemoglobin > 9 g/dL; patients may be transfused or receive erythropoietic treatment to meet this criterion
+Hemoglobin >= 10 g/dL (not requiring red blood cell [RBC] transfusions)
+Hemoglobin (Hb) value > 9 g/dL
+Hemoglobin >= 8 g/dl (may receive transfusions)
+Hemoglobin > 10.0 g/dL =< 28 days prior to registration
+Hemoglobin >= 8.0 g/dL (may be supported by erythropoietin)
+Hb <70 g/L (<7.0 g/dl) and/or transfusion dependency
+Hemoglobin >= 9 g/dL (>= 80 g/L; may be transfused)
+Hemoglobin >= 10 gm/dL (transfusion is allowed to reach minimum level)
+Hemoglobin greater than 8.0 g/dl; subjects may be transfused to reach this cut-off
+Hemoglobin >= 10 g/dl (may achieve by transfusion)
+Hemoglobin > 9 g/dL (standard international [SI] units: 90 g/L)
+Hemoglobin 8.0 g/dL (may receive red blood cell [RBC] transfusions)
+Obtained =< 14 days prior to registration: Hemoglobin >= 8.0 g/dL
+Hemoglobin >= 10 g/dL without transfusion within 4 days prior to enrollment
+Patients must have symptomatic anemia untransfused with hemoglobin =< 9.5 g/dL within 8 weeks of registration or with red blood cell (RBC) transfusion-dependence (i.e., >= 2 units/month) confirmed for a minimum of 8 weeks before randomization
+PART II: Absolute hemoglobin >= 9.0 gm/dL
+Hemoglobin >= 8 g/dL (transfusions are permissible)
+Hemoglobin >= 9 g/dl (pre transfusion values used for prognostic factor, can be transfused or use recombinant erythropoietin growth factors but must not have active bleeding)
+Hemoglobin >= 9 g/dL, within 16 days of starting therapy
+Hemoglobin: >= 8.0 gm/dl (may transfuse peripheral red blood cells [PRBCs])
+Hemoglobin greater than 8.0 g/dl; subjects may be transfused to reach this cut-off
+Performed within 10 business days of treatment initiation with the exception of beta- HCG (72 hours), if applicable: Hemoglobin >= 8 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment).
+Hemoglobin >= 9.0 g/dL within 14 days prior to first dose of protocol-indicated treatment.
+TREATMENT WITH SJCAR19: Hemoglobin > 8 g/dl (can be transfused)
+Hemoglobin >= 9/g/dL (may have been transfused).
+Within 14 days of the first dose of study drug: Hemoglobin >= 9.0 g/dL
+Hemoglobin < 9 g/dL (< 5.5 mmol/L; previous red blood cell [RBC] transfusion is permitted)
+At time of registration and within 4 weeks prior to initiating on-protocol treatment: Hemoglobin >= 9 g/dL or >= 5.6 mmol/L
+Hemoglobin > 8.0 g/dl. Subjects may be transfused to reach this cut-off.
+Hemoglobin >= 10 g/dL with no blood transfusion in the past 28 days, =< 5 days prior to C1D1
+Should be performed within 10 days of treatment initiation: hemoglobin ? 9.0 g/dL
+Hemoglobin ?9.0 g/dL (must be >2 weeks post-red blood cell transfusion)
+Obtained ? 14 days prior to registration: Hemoglobin ? 8.0 g/dL
+Hemoglobin >= 9 g/dL (transfusions allowed)
+Within 10 days prior to the start of study treatment: Hemoglobin >= 9.0 g/dL or >= 5.6 mmol/L
+Hemoglobin ? 8.0 g/dl (red blood cell (RBC) transfusions are permitted)
+Hemoglobin > 8.0 g/dl; subjects may be transfused to reach this cut-off
+Hemoglobin >= 9 g/dL (transfusion to meet eligibility allowed)
+Performed within 10 days of treatment initiation: Hemoglobin ? 9 g/dL or ? 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)
+Hemoglobin ? 8 g/dL, with or without transfusion support
+Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment), should be performed within 10 days of treatment initiation
+Within 7 days of enrollment and with 24 h of starting lymphodepleting chemotherapy: Hemoglobin >= 9.0 g/dL (transfusion allowed).
+Hemoglobin >= 8.5 g/dL, performed within 14 days prior to day 1 of protocol therapy
+Hemoglobin concentration ? 9.0 g/dL.
+Within 28 days prior to treatment start: Hemoglobin >= 9 g/dL
+Hemoglobin >= 9.0 g / dl obtained =< 14 days prior to study initiation
+STRATUM A: Hemoglobin >= 8.0 g/dL without support of a blood transfusion within 7 days of the test
+STRATUM B: Hemoglobin >= 8.0 g/dL without support of a blood transfusion within 7 days of the test
+STRATUM C: Hemoglobin >= 8.0 g/dL without support of a blood transfusion within 7 days of the test
+Hemoglobin >= 9 g/dL, with no blood transfusions in the 28 days prior to study entry
+Hemoglobin >= 8 g/dL without transfusion or erythropoietin (EPO) dependency
+Hemoglobin >= 9 g/dL without transfusion within 1 week preceding study drug administration.
+Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment), performed within 10 days of treatment
+Hemoglobin ? 9 g/dL or ? 5.6 mmol/L within 21 days of treatment initiation without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)
+Hemoglobin >= 8 g/dL or >= 5.0 mmol/L within 21 days of treatment initiation
+Performed within 10 days of treatment initiation: hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)
+Hemoglobin greater than 8.0 g/dl; subjects may be transfused to reach this cut-off
+Obtained within 21 days prior to cycle 1, day 1: hemoglobin >= 10 g/dl
+Hemoglobin: >= 8 g/dL (may be transfused)
+Should be performed within 30 days of treatment initiation: hemoglobin ? 8 g/dL
+Within 28 days of cycle 1 day 1: Hemoglobin\t>= 8 g/dL
+Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment) (performed within 10 days of treatment initiation)
+Within 5 days prior to the start of study treatment: Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment).
+STUDY TREATMENT: Hemoglobin >= 9.0 g/dL within 14 days prior to the first study treatment.
+COHORT 1: HORMONE RECEPTOR POSITIVE BREAST CANCER: Hemoglobin >= 9 mg/dL (transfusion to obtain hemoglobin >= 9 mg/dL within 24 hours prior to dosing is allowed)
+COHORT 2: TRIPLE NEGATIVE BREAST CANCER: Hemoglobin >= 9 mg/dL (transfusion to obtain hemoglobin >= 9 mg/dL within 24 hours prior to dosing is allowed)
+COHORT 3: ENDOMETRIAL CANCER: Hemoglobin >= 9 mg/dL (transfusion to obtain hemoglobin >= 9 mg/dL within 24 hours prior to dosing is allowed)
+Obtained within 14 days prior to randomization/registration: hemoglobin > 9.0 g/dL
+Hemoglobin > 8 g/dL; patients may be transfused to achieve this value; elevated indirect bilirubin due to post transfusion hemolysis is allowed
+Hemoglobin A1C < 6.5%, within 2 weeks of registration
+Within 28 days prior to administration of study treatment: Hemoglobin >= 10 g/dL with no pack red blood cell transfusion in the past 28 days
+Hemoglobin >= 8.0 g/dl, with or without transfusion
+Hemoglobin ?8 grams per deciliter (g/dL)
+Within two weeks prior to enrollment: Hemoglobin >= 9 gm/dL and > 7 days since last red blood cell transfusion
+Hemoglobin >= 9.0 g/dL within 90 days prior to randomization
+Hemoglobin >= 8 g/dL (may be supported), within 14 days of registration and within 7 days of the start of treatment
+Hemoglobin (Hb) ? 9
+Hemoglobin >= 9.0 g/dL (may receive packed red blood cell [prbc] transfusion)
+Obtained within 28 days prior to the first dose of cabozantinib: hemoglobin >= 9 g/dL.
+Hemoglobin 9 g/dl or more; (transfusion permitted)
+To be performed within 14 days prior to day 1 of protocol therapy: hemoglobin (HgB) >= 9.0 g/dL\r\n* NOTE: transfusion of blood products are not allowed to normalize baseline blood parameters, however subsequent transfusions are allowed per standard supportive care guidelines
+Hemoglobin < 9 g/dL at the screening visit at the screening visit
+Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)
+Hemoglobin level <= 10.0 gram per deciliter (g/dL)
+Hemoglobin 9 g/dl or more; (transfusion permitted)
+Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment), performed within 14 days of treatment initiation
+Hemoglobin >= 9 g/dL or >= 5.6 mmol/L, performed within 28 days of treatment initiation
+Within 3 days before the first dose of study drug: hemoglobin > 8 g/dL (prior red blood cell [RBC] transfusion allowed); patients may be transfused to achieve this value; elevated indirect bilirubin due to post-transfusion hemolysis is allowed
+Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)
+Hemoglobin >= 10 g/dL obtained =< 14 days prior to registration
+Obtained within 14 days of the first study treatment: Hemoglobin > 9 g/dL
+Hemoglobin ? 9 g/dL (may have been transfused)
+To be performed within 14 days of treatment initiation: hemoglobin ? 9 g/dL or ? 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)
+Hemoglobin ? 8 g/dL within 14 days of treatment initiation
+Hemoglobin > 8.0 g/dL; subjects may be transfused to reach this cut-off
+Hemoglobin > 8 g/dL (may be supported)
+Obtained =< 14 days prior to registration: Hemoglobin >= 9.0 g/dL
+Hemoglobin > 8.0 mg/dL within 14 days of treatment initiation
+Within 10 days of treatment initiation: Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment).
+Hemoglobin > 9.0 g/dL within 14 days of study registration
+Within 14 days of treatment initiation: Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)
+Hemoglobin >= 9.0 g/dL, obtained within 7 days prior to first study treatment
+Performed within 10 days of treatment initiation: Hemoglobin >= 8 g/dL
+Hemoglobin >= 9.0 g/dL independent of transfusion.
+Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment).
+Patients with blood or platelet transfusion within 1 week prior to signing Consent A, or with platelets < 50,000/mm^3, neutrophils < 750/mm^3, or hemoglobin < 8.5 g/dL, unless the cytopenias are considered by the treating physician to be largely due to marrow involvement by lymphoma
+Within 7 days of registration: Hemoglobin >= 9.0 g/gL or >= 5.6 mmol/L, without recent transfusion
+Obtained =< 14 days prior to registration: Hemoglobin > 9.0 g/dL or >= 5.6 mmol/L without transfusion or (EPO) erythropoietin dependency (within 7 days of assessment)
+Within 14 days of the first dose of the study drugs: Hemoglobin >= 9 g/dl (treatment allowed).
+Hemoglobin >= 9 g/dl (patients may be transfused to this level).
+Within 10 days prior to on-study date: Hemoglobin ? 9 g/dL (or ? 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)
+Hemoglobin ? 8 g/dL within 10 days prior to “on study” status
+Hemoglobin >= 9 g/dL but transfusion allowed
+Hemoglobin > 9.0 g/dL within 14 days of registration
+Hemoglobin >= 9 g/dL without transfusion or erythropoietin (EPO) dependency within 7 days
+Within 7 days prior to administration of study treatment: Hemoglobin >= 10.0 g/dL (unless due to bone marrow infiltration by tumor, in which case hemoglobin >= 8 g/dL is allowed) and no blood transfusions in the 7 days prior to entry.
+Within 28 days prior to enrollment: Hemoglobin >= 9 g/dL
+Hemoglobin >= 9g/dL (transfusion permitted)
+Hemoglobin >= 9.0 g/dL within 14 days of study registration. Patients must not be transfused for at least 14 days prior to study entry.
+Hemoglobin ? 8 g/dL (red blood cell [RBC] transfusion is allowed)
+Hemoglobin >= 9 g/dL (transfusions permitted)
+Obtained with 21 days of registration: hemoglobin >= 8 g/dL
+Hemoglobin >= 8.0 g/dl (red blood cell [RBC] transfusions are permitted) must be met during screening (within 21 days) and also prior to study drug administration on cycle 1 day 1
+Within 10 days of treatment initiation: Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)
+Obtained within 21 days prior to randomization/registration: Hemoglobin > 9.0 g/dL.
+Hemoglobin ? 9 g/dL (uncorrected by RBC transfusion)
+Within 14 days prior to registration: Hemoglobin >= 8.0 mg/dl (transfusions are permitted to achieve baseline hemoglobin level)
+Hemoglobin (Hb) at least 8.0 grams per deciliter (g/dL) at baseline (blood transfusions are allowed during the screening period to correct Hb values less than 8.0 g/dL).
+Within 10 days of treatment initiation: Hemoglobin ? 9 g/dL or ? 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)
+Hemoglobin (Hgb) >= 9 g/dL with or without packed red blood cells (pRBC) transfusion
+Hemoglobin ? 9 g/dL or ? 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)
+Hemoglobin (Hb) at least 9 g/dL (or 5.69 mmol/L) at baseline (blood transfusions, hematopoietic growth factors and hematinics are not allowed during the 7 days prior to screening to correct Hb values less than 9 g/dL)
+Obtained within 14 days of the first study treatment: Hemoglobin > 9 g/dL
+Patient has a hemoglobin value <10 g/dL at Screening
+Hemoglobin >= 8 g/dL; RBC transfusions and use of G-CSF will be allowed in order to meet eligibility parameters (unless dysfunction is secondary to lymphoma involvement)
+Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment) (performed within 10 days of treatment initiation)
+Within 14 days of the first dose of study drug: Hemoglobin (Hgb) > 9.0 g/dL (may be transfused or receive epoetin alfa [e.g., Epogen] to maintain or exceed this level)
+Performed within 10 days of treatment initiation: Hemoglobin >= 9 g/dL or >= 5.6 mmol/L\r\n* Patients cannot have received transfusion or erythropoietin (EPO) within 7 days of the hemoglobin (Hgb) lab test
+Within 7 days (+ 3 day window) of enrollment: Hemoglobin >= 9.0 g/dL
+REP ELIGIBILITY: Hemoglobin greater than or equal to 8.0 g/dL (Note that this threshold is slightly lower than the initial trial screening parameter since most subjects will require blood transfusion at some point during the protocol treatment, and the established threshold for transfusion is 8 gm/dL)
+CHEMOTHERAPY/CELL INFUSION ELIGIBILITY: Hemoglobin greater than or equal to 8.0 g/dL (Note that this threshold is slightly lower than the initial trial screening parameter since most subjects will require blood transfusion at some point during the protocol treatment, and the established threshold for transfusion is 8 gm/dL)
+Hemoglobin >= 9 g/dL, unsupported by transfusions (within 14 days of study registration)
+Within 7 days before the first dose of study treatment: Hemoglobin >= 9 g/dL
+Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)
+Hemoglobin >= 9 g/dL results within 7 days before study drug administration
+Hemoglobin >= 8 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment), performed within 10 days of treatment initiation
+Hemoglobin < 9.0 g/dL (patients may be transfused above this threshold)
+Obtained =< 14 days prior to registration: Hemoglobin >= 9.0 g/dL
+Hemoglobin >= 8 g/dL without red blood cell transfusions within 2 weeks of the initiation of treatment
+Hemoglobin ? 9 g/dL (may have been transfused)
+No more than 14 days prior to registration: Hemoglobin >= 9.0 g/dL
+Obtained =< 28 days prior to registration: Hemoglobin >= 9.0 g/dL without transfusion or erythropoietin (EPO) dependency (=< 7 days prior to assessment)
+Performed within 7 days of treatment initiation: Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)
+Hemoglobin > 9 g/dL, without transfusion or hematopoietic growth factor
+Performed within 14 days of treatment initiation: Hemoglobin >= 9 g/dL
+Hemoglobin ? 9.0 g/dL without transfusion support within 14 days prior to study treatment (erythropoietin or darbepoetin permitted)
+Hemoglobin >= 9.0 g/dL (prior transfusion permitted) within 14 days of cycle 1 day 1
+Obtained within 14 days prior to the first study treatment (cycle 1, day 1): hemoglobin >= 9.0 g/dL
+Hemoglobin >= 10.0 g/dL with no blood transfusion within 28 days of starting treatment
+Within 14 days of the first study treatment: Hemoglobin >= 9 g/dL (may have been transfused)
+Hemoglobin ?9.0 grams per deciliter (g/dL)
+Hemoglobin >= 8 g/dL without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment), performed within 14 days of treatment initiation
+Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment), performed within 10 days of treatment initiation
+Within 14 days prior to registration: Hemoglobin >= 9 g/dL
+Hemoglobin >= 10 g/dL obtained =< 14 days prior to registration
+Obtained within 14 days prior to enrollment: hemoglobin >= 9 g/dL
+(For both cohorts A and B): Hemoglobin (Hb) > 9 G/dL
+Hemoglobin >= 9 g/dL, performed within 14 days of protocol registration
+Hemoglobin ? 9.5 grams/dL
+Hemoglobin (Hb) > 9 g/dL; blood transfusion to meet the inclusion criteria will not be allowed
+Hemoglobin >= 8.0g/dl (may receive red blood cell [RBC] transfusions)
+Participants with hemoglobin level >= 8 g/dL, within 21 days of initiation of protocol therapy; transfusion may be used to meet hemoglobin eligibility criteria
+Participants with hemoglobin level < 8 g/dL, within 21 days of initiation of protocol therapy; transfusion may be used to meet hemoglobin eligibility criteria
+Hemoglobin level <9.0 gm/L
+Hemoglobin ? 9.5 grams/dL
+Hemoglobin >= 9 g/dL (may have been transfused)
+Hemoglobin > 9.0 g/dL obtained =< 7 days prior to registration
+Hemoglobin >= 9 g/dL (may have been transfused)
+Performed within 10 days of treatment initiation: Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)
+Obtained within 14 days of randomization: Hemoglobin >= 9.0 g/dL
+Hemoglobin >= 8 (with or without transfusion)
+Determined within 3 weeks of treatment initiation: Hemoglobin >= 8.0 g/dl
+Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)
+Hemoglobin ? 8.0 g/dL (may receive transfusions)
+Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)
+Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)
+Hemoglobin >= 10.0 g/dL with no blood transfusion in the past 28 days, measured within 28 days prior to administration of study treatment
+Hemoglobin > 8.0 g/dL independent of transfusion and growth factor support for at least 7 days prior to screening (except for pegylated G-CSF [pegfilgrastim] and darbepoetin which require at least 14 days prior to screening)
+Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)
+Hemoglobin >= 9 gm/dl prior to biopsy (can be transfused)
+Hemoglobin (Hb) ?5.5 and ?10.5 g/dL during screening
+Hemoglobin >= 8.0 g/dL obtained =< 14 days prior to registration
+Within 10 days of treatment initiation: Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)
+Hemoglobin >= 9.0 g/dL (transfusion is allowed to correct anemia).
+Within 14 days prior to the first study treatment (cycle 1, day 1): Hemoglobin >= 9.0 g/dL
+Performed within 14 days (+ 3 working days) prior to registration: Hemoglobin > 10 gm/dl (may be reached by transfusion).
+Hemoglobin >= 9.0 g/dL (obtained =< 14 days prior to registration)
+Hemoglobin >= 8 mg/dL (Note: Transfusion may be used for eligibility outside of 7 days)
+DONOR: Hemoglobin within 10% of upper and lower limit of normal range of test (gender based for hemoglobin)
+Hemoglobin >=8 gram per deciliter (g/dL).
+Within 14 days of treatment initiation: Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)
+Hemoglobin >= 10.0 gm/dL (may receive red blood cell count [RBC] transfusions)
+Within 14 days of registration: Hemoglobin >= 10.0 g/dL
+Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment), performed within 14 days of registration
+Hemoglobin ? 9 g/dL (transfusions are allowed)
+Hemoglobin level >= 8.0 gm/dL on screening complete blood count
+Hemoglobin >= 9.0 g/dL within 28 days prior to study registration
+Hemoglobin (Hb) > 9.0 g/dL within 7 days prior to enrollment; Note: the use of transfusion or other intervention to achieve Hb >= 9.0 g/dL is acceptable
+Hemoglobin >= 9 g/dL without transfusion within 1 week preceding study drug administration
+FOR AML ONLY: Obtained =< 14 days prior to registration: Hemoglobin >= 7.5 g/dl
+FOR TCL ONLY: Obtained =< 14 days prior to registration: Hemoglobin >= 8.5 g/dl
+Platelet transfusion and packed red blood cell transfusion can also be given prior to the start of treatment and treatment to achieve a target plt >= 75,000/uL and hemoglobin of >= 8.5 g/dl, provided that patients have not received growth factors for at least 14 days prior to entering trial
+Hemoglobin >= 9 g/dl (treatment allowed) within 14 days prior to study entry
+Hemoglobin ? 9.0 g/dL within 14 days prior to the first study treatment (cycle 1, day 1)
+To be performed within 10 business days prior to day 1: Platelets >= 50,000/mm^3; NOTE: platelet transfusion and packet red blood cell transfusion can be given prior to enrollment to achieve a target platelet (Plt) >= 50,000/uL and hemoglobin of >= 8.5 g/dL
+To be performed within 10 business days prior to day 1: Hemoglobin >= 8.5 g/dL
+Hemoglobin >= 8.0 g/dL, obtained =< 14 days prior to registration
+Hemoglobin > 8 g/dL; patients may be transfused to receive this value; elevated indirect bilirubin due to post-transfusion hemolysis is allowed
+Hemoglobin (no transfusion within prior 7 days) >= 9.0 g/dL
+Hemoglobin >= 9.0 g/dL (5.6 mmol/L) obtained =< 14 days prior to registration; NOTE: transfusions are not allowed =< 7 days prior to registration
+Performed within 10 days of treatment initiation: Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)
+Hemoglobin >= 9/g/dL (may have been transfused)
+Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)
+Hemoglobin >= 9 g/dL without transfusion within 1 week preceding study drug administration
+Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)
+Hemoglobin >= 9 prior to biopsy
+Hemoglobin >= 9.0 g/dL\r\n* Patients may have a transfusion of red blood cells to meet the hemoglobin requirement
+Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment) (performed within 28 days of registration)
+Hemoglobin >= 8 g/dL performed within 10 days of treatment initiation (red blood cell [RBC] transfusions are OK)
+Hemoglobin >= 9 g/dL (transfusion allowed but must demonstrate stability after transfusion)
+Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)
+Hemoglobin >= 10.0 g/dl; use of transfusion or other intervention to achieve this hemoglobin level is acceptable
+Hemoglobin > 8.0 g/dL should be obtained within 21 days prior to enrollment
+Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)
+Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)
+Hemoglobin more or equal than 2 grams/dL below the institutional level of normal
+Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment) (within 10-15 days of treatment initiation)
+Hemoglobin >= 10 g/dL (no blood transfusion in the 28 days prior to entry [olaparib guidelines])
+Hemoglobin >= 8 g/dL within 16 days of treatment initiation
+Hemoglobin >= 9.0 g/dL, independent of transfusion and/or growth factors within 3 months prior to randomization
+Hemoglobin >= 10 g/dL (transfusion to obtain hemoglobin >= 10 g/dL within 24 hours prior to dosing is allowed)
+Hemoglobin >= 10 g/dl at cycle 1 day 1 of TPF
+RBC transfusion-dependent anemia defined as: anemia requiring RBC transfusions of at least 1 unit of RBC every 6 weeks for hemoglobin =< 9.0 g/dL
+Hemoglobin >= 8 g/dL without transfusion or erythropoietin (EPO) dependency within 7 days performed within 7 days of treatment initiation performed within 7 days of treatment initiation
+Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment), during screening and on cycle 1, day 1
+Hemoglobin < 8.0 g/dL (transfusion permitted at least 7 days prior to baseline)
+Hemoglobin: >= 8 g/dL (may be transfused)
+Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment) within 14 days of treatment initiation
+Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 14 days of assessment) (performed within 10 days of treatment initiation)
+Obtained within 14 days prior to registration; hemoglobin ? 9 g/dl
+Within 60 days prior to registration, hematologic minimal values: hemoglobin > 8.0 g/dl
+Hemoglobin (Hb) level < 8 gm/dl
+Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)
+Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)
+Within 10 days of treatment initiation: Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)
+Obtained =< 14 days prior to randomization: Hemoglobin >= 9.0 g/dL
+Hemoglobin: >= 9 g/dL or 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)
+Hemoglobin >= 8.0 g/dL (transfusion permitted)
+Hemoglobin >= 10 g/dL (not requiring red blood cell [RBC] transfusions)
+Completed within 60 days of surgery: Hemoglobin ? 9.0 g/dL
+Completed within 10 days of SBRT treatment initiation: Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)
+Hemoglobin >= 8.5 g/dL (without the use of growth factors) (within 14 days prior to registration)
+Hemoglobin >= 9 g/dL\r\n* May receive transfusion to meet this goal
+Hemoglobin >= 9 g/dL\r\n* Note: Patients requiring transfusion to meet the hemoglobin requirement are not eligible for the study
+Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)
+Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)
+Hemoglobin >= 8.0 g/dL within first 2 weeks prior to first dose of investigational product
+Hemoglobin >= 7 g/dL or >= 5.6 mmol/L within 14 days prior to registration
+Within 14 days prior to registration: Hemoglobin (Hb) > 10.0 g/dL (can be transfused to this level)
+Hemoglobin < 9.0 gm/dL (SI units gm/L)
+PART 2 GROUP 1 INCLUSION CRITERIA: Hemoglobin (Hgb) >= 8 g/dL (may receive red blood cell [RBC] transfusion)
+Hemoglobin of >= 10 g/dL, independent of transfusion and/or growth factors within 3 months prior to randomization
+PHASE I: Hemoglobin >= 9 g/dl, and no blood transfusion within 4 weeks; OR > 10 g/dL, and no blood transfusion within 2 weeks
+PHASE II SCLC: Hemoglobin >= 9 g/dl, and no blood transfusion within 4 weeks; OR > 10 g/dL, and no blood transfusion within 2 weeks
+UROTHELIAL CARCINOMA EXPANSION COHORT: Hemoglobin >= 10 g/dL in the absence of packed red blood cells transfusion 28 days prior to dosing OR > 9 g/dL, if the value is constant across 2 readings within 2 weeks in the absence of packed red blood cells transfusion 28 days prior to dosing
+mCRPC EXPANSION COHORT: Hemoglobin >= 9 g/dL
+Hemoglobin >= 8 g/dL, performed within 10 days of treatment initiation
+Hemoglobin >= 9 g/dL, with or without transfusion support; NOTE: If the patient’s bone marrow biopsy shows greater than or equal to 50% plasma cells, hemoglobin > 8 g/dL (transfusion support or growth factor support is acceptable)
+Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency\r\n(within 7 days of assessment)
+Patients must have hemoglobin >= 8.5 g/dl; platelet transfusion and packed red blood cell transfusion can also be given prior to the start of treatment and during treatment to achieve a target hemoglobin of >= 8.5/ul provided that patients have not received growth factors for at least 14 days prior to entering trial
+Anemia or red blood cell (RBC)-transfusion dependence defined as follows: a) Anemia: defined for the purpose of this protocol as 1) a hemoglobin level < 10 g/L on every determination over 84 days before study-entry, without RBC-transfusions, or 2) a hemoglobin level < 10 g/L on a patient that is receiving RBC-transfusions periodically but not meeting criteria for transfusion-dependent patient as defined below; the baseline hemoglobin value for these subjects is the lowest hemoglobin level during the antecedent 84 days; b) RBC-transfusion-dependence: RBC-transfusion-frequency of >= 2 units packet red blood cell (PRBC)/28 days averaged over 84 days immediately pre-study-entry; there must not be any consecutive 42 days without an RBC-transfusion during this interval
+Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)
+Hemoglobin >= 9 g/dL without transfusion within 1 week preceding study drug administration
+Hemoglobin >= 9.0 g/dL, independent of transfusion and/or growth factors within 3 months prior to randomization
+Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)
+Bone marrow reserve consistent with: hemoglobin >= 9 g/dL values must be obtained without the need for myeloid growth factor support, platelet or PRBC transfusion support within 14 days
+Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)
+Hemoglobin > 10.0 g/dL (transfusion and/or erythropoiesis stimulating agents [ESA] allowed)
+Hemoglobin >= 7.5 g/dL in the presence of bone marrow involvement independent of transfusion and/or growth factors within 3 months prior to enrollment
+Performed 28 days prior to study registration up to the first dose of study drug: hemoglobin >= 9 g/dL or >= 5.6 mmol/L
+Within 10 days of treatment initiation: Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)
+Hemoglobin >= 8 g/dL without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment), performed within 10 days of treatment initiation
+Hemoglobin >= 9 g/dL (may transfuse or use erythropoietin to achieve this level)
+Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)
+Hemoglobin >= 9 g/dl (no blood transfusions within 4 weeks prior to enrollment)
+Hemoglobin >= 8.0 g/dl (eligibility level for hemoglobin may be reached by transfusion)
+Performed within 14 days (+3 working days) of treatment initiation: Hemoglobin >= 9 g/dL or >= 5.6 mmol/L
+Hemoglobin if anemia attributed to KS, KSHV-MCD, or KICS >= 7 gm/dL, otherwise >= 8 gm/dL (Group II)
+Hemoglobin ? 9.0 g/dL (in the absence of transfusion within 2 weeks before randomization)
+Hemoglobin >= 8 g/dL without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)
+hemoglobin ? 9.0 g/dL (transfusions permissible)
+Hemoglobin >= 9.0 g/dL, which must be stable in the opinion of the investigator without a history of transfusion dependence
+Hemoglobin >= 8.0 mg/dL without red blood cell transfusion =< 7 days prior to C1D1
+Performed within 14 days of treatment initiation: Hemoglobin >= 8 g/dL or >= 5.6 mmol/L
+Hemoglobin > 9.0 g/dL obtained within 14 days prior to randomization/registration
+Hemoglobin >= 9.0 g/dL (patients may be transfused to meet this criterion)
+Hemoglobin >= 9 g/dL without transfusion dependency
+Hemoglobin >= 8 g/dL without red blood cell transfusions within 2 weeks of the initiation of treatment
+Hemoglobin > 8g/dL (may receive transfusions).
+Hemoglobin >= 9 g/dL or >= 5.6 mmol/L except in cases of marrow infiltration by lymphoma
+Within 14 days of first dose of study drug administration: Hemoglobin >= 9.0g/dl
+Hemoglobin >= 9 g/dL without transfusion within 7 days prior to enrollment
+Hemoglobin >= 10 gr/dL
+Hemoglobin < 10 gr/dL
+Hemoglobin concentration > 8 g/dL (with or without support)
+Hemoglobin >= 9 g/dL qualifications (transfusion permitted)
+Hemoglobin >= 9.0 g/dL and no blood transfusions in the 28 days prior to enrollment
+Hemoglobin > 9 g/dL (untransfused)
+ADDITIONAL CRITERIA FOR STUDY CONTINUATION: Hemoglobin >= 9 gm/dl
+Performed within 28 days prior to study registration up to the first dose of study drug: Hemoglobin >= 9 g/dL or >= 5.6 mmol/L
+hemoglobin greater than or equal to 8.0 grams/deciliter (g/dL) (a hemoglobin less than 8.0 g/dL is acceptable if it is corrected by growth factor or transfusion before starting lenvatinib).
+Hemoglobin >= 9.0 g/dL without transfusion support within the past 28 days (erythropoietin or darbepoetin permitted)
+Hemoglobin (Hb) >= 6.0 mmol/L
+Hemoglobin >= 9 g/dL or >= 5.6 mmol/L, performed within 10 days of treatment initiation
+Hemoglobin >= 9.0 g/dL with last transfusion at least 14 days before day 1 of study drug
+Hemoglobin greater than 8.0 g/dL (transfusion independent; no transfusion for >= 7 days prior to study enrollment)
+Hemoglobin < 9.0 g/dL; patients may not be transfused to meet enrollment criteria
+Hemoglobin 10 gl/dl (transfusion allowed)
+Hemoglobin >= 9 g/dL (packed red blood cell [pRBC] transfusion +/- erythropoiesis-stimulating agents [ESA] are allowed) (must be within 7 days of MLA)
+Performed within 10 days of treatment initiation; hemoglobin ? 9 g/dL or ? 5.6 mmol/L
+Hemoglobin > 8 g/dl (may be transfused)
+Must be met within 28 days of C1D1: Hemoglobin >= 9.0 g/dl
+Hemoglobin > 8 gm/dL, patients may be transfused with red blood cells (RBC’s)
+Hemoglobin > 8.0 g/dL; may transfuse to meet eligibility
+Hemoglobin >= 8 g/dL (may be post-transfusion)
+Hemoglobin >= 10 gm/dL prior to biopsy
+Within 4 days prior to the first dose of cabozantinib: Hemoglobin >= 9 g/dL
+Hemoglobin >= 8.5 mg/dl obtained within 28 days prior to registration
+Hemoglobin (Hb) level < 9 g/dL
+Hemoglobin >= 9 g/dL, obtained within 30 days of study registration
+Hemoglobin >= 9.0 mg/dL without transfusion in 2 prior weeks
+Hemoglobin >= 9 g/dL (SI units 90 g/L) (in the absence of transfusion within 24 hours prior to dosing)
+Hemoglobin (Hgb) > 9.0 g/dL (may be transfused or receive epoetin alfa [e.g., Epogen] to maintain or exceed this level) within 14 days of the first dose of study drug
+Hemoglobin (Hb) >= 9.0 g/dL (transfusion independent)
+Hemoglobin < 8.0 g/dl (the patient may be transfused prior to study entry)
+Hemoglobin >= 9 g/dl (patients may be transfused to this level)
+Hemoglobin >= 8 g/dL (80 g/L) (subjects may be receiving red blood cell [RBC] transfusions in accordance with institutional guidelines)
+Hemoglobin >= 9 g/dL (>= 80 g/L; may be transfused)
+Hemoglobin >= 8 g/dL (80 g/L) within 14 days prior to starting therapy (subjects may be receiving red blood cell [RBC] transfusions in accordance with institutional guidelines)
+Hemoglobin < 8.0 g/dl (the patient may be transfused prior to study entry)
+Hemoglobin <9 g/dL (may receive transfusion or erythropoietin to maintain)
+Hemoglobin >= 9 g/dL (may be transfused to maintain or exceed this level)
+Hemoglobin >= 8.0 g/dL without transfusion if stem cells are not available
+Hemoglobin > 8.0 gm/dL, transfusion allowed
+Hemoglobin > 8 g/dl (may be transfused)
+Hemoglobin >= 8 g/dL (transfusion permitted)
+Hemoglobin >= 8 g/dL (packed red blood cell [PRBC] transfusions permitted)
+Hemoglobin >= 9.0 g/dL (after transfusion if required)
+Hemoglobin >= 10 gm/dl; eligibility level for hemoglobin may be reached by transfusion
+Hemoglobin >= 9 g/dL (5.6 mmol/L); subjects may not have had a transfusion within 7 days of screening assessment
+Hemoglobin >= 8 g/dL; this value must be obtained within four weeks before protocol entry
+Hemoglobin >= 8.0 g/dl; subjects may be transfused to reach this cut-off
+Hemoglobin >= 10 gm/dL (performed within 14 days prior to registration); eligibility level for hemoglobin may be reached by transfusion
+Hemoglobin (Hb) >= 9 g/dL (independent of transfusion and/or growth factors within 3 months prior to cycle 1 day 1)
+Hemoglobin >= 8 g/dl (may receive transfusions)
+Hemoglobin >= 8.0 g/dL obtained =< 14 days prior to registration
+Hemoglobin >= 8 g/L, at screening
+Hemoglobin greater than 10 gm/dL (can be transfused); hemoglobin < 10 gm/dL due to operative blood loss is permitted
+Hemoglobin < 8.0 g/dl (the patient may be transfused prior to study entry)
+Hemoglobin (Hgb) greater than 8.0 g/dL (may have packed red blood cell [PRBC] transfusion)
+Hemoglobin > 8 g/dl (may be transfused)
+Platelet count should be > 50,000/ul and hemoglobin should be > 8 gm/dl; patients may receive platelet or red blood cell transfusions to maintain hemoglobin and platelets at clinical appropriate levels
+Hemoglobin >= 9 g/dL; continuation of erythropoietin products is permitted; hemoglobin must be stable above 9 g/dL for at least 2 weeks without blood transfusion to maintain hemoglobin level
+Hemoglobin < 8.0 g/dl (the patient may be transfused prior to study entry)
+patients who have a minimum hemoglobin level of 9
+Hemoglobin >= 9.0 gm/dL (may be a post transfusion value)
+Hemoglobin > 8 gm/dL without transfusion and off erythropoietin for 14 days or darbepoetin (Aranesp) for 21 days
+Hemoglobin <9 gm/dl for males; < 8.5 gm/dl for females.
+Hemoglobin ?9 g/dL, without transfusion support within 7 days preceding the lab assessment.
+Hemoglobin (Hgb) ? 9 g/dL. NOTE: subject must not have received any growth factor or blood transfusions within 14 days prior to the hematology values obtained at screening. Subjects requiring transfusions to meet eligibility criteria are not eligible.
+Hemoglobin ? 9 g/dL OR ? 8 g/dL if anemia due to iBCL, without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)
+Hemoglobin at least 8.0 grams per deciliter (g/dL) at Baseline (blood transfusions are allowed during the screening period to correct hemoglobin values less than 8.0 g/dL) As blood transfusions are permitted to meet the hemoglobin criteria, participants requiring transfusion must not be known to be refractory to red blood cell or platelet transfusions.
+Hemoglobin >= 8.0 g/dL (may transfuse to meet this requirement), obtained =<14 days prior to registration
+Hemoglobin ? 9 g/dL (without transfusion for at least one month)
+Obtained =< 14 days prior to registration: Hemoglobin >= 8.0 g/dL
+Hemoglobin (>=) 7.5 gram per deciliter (g/dL) ([>=] 5 millimole per liter [mmol/L]; prior red blood cell [RBC] transfusion is permitted)
+Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment), should be performed within 10 days of treatment initiation
+Hemoglobin level <= 10.0 gram per deciliter (g/dL)
+Hemoglobin >= 7 g/dL or >= 5.6 mmol/L with transfusion or erythropoietin (EPO) dependency
+Hemoglobin >= 8.0 grams/dL
+Hemoglobin > 8.0 mg/dL (without transfusion in the preceding 7 days)
+Hemoglobin >= 8 g/dL; patients may be transfused to achieve this value; elevated indirect bilirubin due to post-transfusion hemolysis is allowed (repeat if more than 3 days before the first dose)
+hemoglobin level lower than 8 g/dL (5.0 mmol/L) or platelet count <75x10^9/L or history of heparin induced thrombocytopenia;
+Hemoglobin >= 8 g/dL; subjects may receive red blood cell transfusions as clinically indicated per institutional guidelines but screening hemoglobin should be independent of red blood cell transfusion for at least 3 days prior to cycle 1 day 1
+Hemoglobin ? 9.0 g/dL; platelets ? 100 x 109/L; absolute neutrophil count ? 1.5 x 109/L without the use of hematopoietic growth factors
+Anemia: normochromic, normocytic with a hemoglobin value of > 2g/100 ml below the lower limit of normal or a hemoglobin value < 10g/100 ml
+Adequate organ function as defined by the following criteria: Absolute neutrophil count (ANC) ? 1500/?l, Platelets ? 140,000/?l,Hemoglobin ? 12.0 g/dl, Creatinine < 2.0 mg/dl
+Hemoglobin >9.0 g/dL (may be maintained by transfusion)
+Hemoglobin ?8.0 g/dL with or without transfusion support
+Hemoglobin >= 8.0 gm/dL (can be transfused)
+Within 14 days prior to randomization: Hemoglobin must be >= 8 g/dL
+Hemoglobin >= 10.0 g/dL with no blood transfusion in the past 28 days.
+Within 28 days prior to administration of study treatment: Hemoglobin ? 10.0 g/dL with no blood transfusion in the past 28 days
+Within 14 days of first dose of study drug: Hemoglobin >= 9 g/dL
+Hemoglobin ? (9.0 g/dL) - patients may be transfused to meet this criterion.
+Hemoglobin > 8.0 gm/dL, transfusion allowed
+REGISTRATION TO TREATMENT (STEP 1): Hemoglobin (Hgb) >= 9.0 g/dL OR >= 5.6 mmol/L without transfusion of erythropoietin (EPO) dependency, within 14 days prior to first dose of pembrolizumab
+Hemoglobin >= 8 g/dL (transfusion allowed)
+Within 14 days of study drug(s) initiation: Hemoglobin (Hgb) >= 10 g/dL with no blood transfusion in the past 14 days.
+Within 14 days prior to the first study treatment (cycle 1, day 1): Hemoglobin >= 9.0 g/dL.
+Part 1: hemoglobin level of ? 8 g/dL within 2 weeks of enrollment\r\n* Packed red blood cell (PRBC) transfusions will be allowed to patients with hemoglobin < 8g/dl
+Hemoglobin >= 8.0 gm/dL within 28 days prior to registration.
+Hemoglobin >= 9 g/dL (transfusion to meet this criterion is allowed)
+Obtained ? 14 days prior to registration: hemoglobin ? 9.0 g/dL
+Hemoglobin >= 10 g/dL. Eligibility level for hemoglobin may be reached by transfusion.
+Hemoglobin ? 9.0 g/dL without transfusion and/or growth factors in the 3 months prior to randomization
+Hemoglobin > 8 g/dL; patients may be transfused to achieve this value
+Hemoglobin ? 9 g/dL or ? 5.6 mmol/L within 7 days of treatment initiation
+Within 14 days prior to first dose of study drug treatment: Hemoglobin >= 9 g/dL without transfusion in the previous week
+Within 7 days before the first dose of cabozantinib: Hemoglobin >= 9 g/dL
+Hemoglobin >= 9 g/dL =< 14 days prior to registration
+All screening labs should be performed within 14 days (+3 working days) of treatment initiation: hemoglobin >= 9 g/dL or >= 5.6 mmol/L;
+Hemoglobin >= 9 g/dL (Note: no transfusion within 56 days. Ongoing growth factor support is acceptable if on a stable dose for the past 56 days), within 28 days of day 0.
+Within 10 days of treatment initiation: hemoglobin >= 9 g/dl without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)
+Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment), performed within 28 days of treatment initiation
+DONORS: Hemoglobin within 10% of upper and lower limit of normal range of test (gender based for hemoglobin)
+Hemoglobin (no transfusion within prior 7 days) >= 9.0 g/dL
+Obtained =< 21 days prior to registration: Hemoglobin > 9.0 g/dL
+Within 10 days of treatment initiation: Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)
+Obtained within 28 days prior to registration: Hemoglobin > 9.0 g/dL
+Hemoglobin >= 8.0 g/dL; if patients have a hemoglobin level below 8, blood transfusion is allowed to meet the eligibility criteria as long as post transfusion hemoglobin is maintained at >= 8.0 g/dL for 7 days or longer
+Blood counts performed within 3 weeks prior to starting study therapy must have hemoglobin >= 9 g/dL
+Hemoglobin (Hgb) > 9 g/dL (without transfusion or erythropoietin [EPO] dependency within 7 days of assessment)
+Hemoglobin >= 9 g/dL (may be transfused to maintain or exceed this level)
+Obtained =< 7 days prior to registration: Hemoglobin >= 9 g/dL
+Hemoglobin >= 9.0 g/dL, obtained within 14 days prior to the first study treatment (cycle 1, day 1)
+Hemoglobin >= 8 g/dL (may receive transfusions)
+Must have adequate organ function as defined by the following values: white blood cells >3 x 10^9/liter(L); absolute neutrophil count (ANC) >= 1.5 x 10^9/L; hemoglobin >= 9 grams per decilitre (g/dL) subjects that required transfusion or growth factor need to demonstrate stable hemoglobin for 7 days of 9 g/dL; platelets >=100 x 10^9/L; prothrombin time (PT)/International normalized ration (INR) and partial thromboplastin time (PTT) <= 1.5 x upper limit of normal (ULN); albumin >=2.5 g/dL; total bilirubin <=1.5 x ULN; aspartate transaminase (AST) <=2.5 x ULN; alanine transaminase (ALT) <=2.5 x ULN OR <5 x ULN; creatinine <=1.5 x ULN is acceptable for subjects with documented liver metastases/tumor infiltration; creatinine clearance >= 50 mL/min; ejection fraction>= lower limit of normal (LLN) by echocardiogram or multigated acquisition (MUGA) and minimum of 50% left ventricular ejection fraction (LVEF); testosterone <=50 nanograms per deciliter (ng/dL)
+Hemoglobin >= 10 g/dL (transfuse as necessary to raise levels, no transfusions within 7 days of start)
+Hemoglobin < 9.0 g/dL (red blood cell transfusion and erythropoietin may be used to reach at least 9.0 g/dL, but must have been administered at least 2 weeks prior to the first dose of study drug.
+Within 14 days prior to registration: Hemoglobin >= 8.0 g/dL
+Hemoglobin >= 9 g/dL without transfusion in the preceding 7 days
+Hemoglobin >= 9.0 g/dL (5.6 mmol/L or 90 g/L) without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment) obtained =< 28 days prior to registration
+Hemoglobin >= 8 gram per deciliter (g/dL).
+Hemoglobin >= 10 g/dL with no blood transfusion in the past 28 days
+Within 28 days of study registration: Hemoglobin value >= 9 g/dL at the screening visit (independent of blood transfusion and/or growth factors within 3 months prior to registration)
+Hemoglobin > 9.0 g/dL – unless determined by treating physician to be disease related, obtained =< 7 days prior to registration
+Hemoglobin >= 8 g/dL; red blood cell transfusions are permitted to meet eligibility criteria
+Heme: Plt Ct ? 100 x 103/µL, ANC ? 1.5 x 103/µL, and Hemoglobin ? 9 g/dL
+Performed within 14 days prior to study: Hemoglobin > 10 gm/dl
+Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment) (performed within 10 days of treatment initiation)
+Hemoglobin > 9 g/dl (blood transfusion is allowed to meet the eligibility criteria as long as post transfusion hemoglobin is maintained at >= 9.0 g/dL for 7 days or longer)
+Hemoglobin >= 9 gm/dL (transfusion permitted)
+Hemoglobin >= 8.0 g/dL (may receive red blood cell [RBC] transfusions)
+TREATMENT: Patients must have >=10.0 g/dL Hb and no blood transfusion in the past 28 days to receive veliparib
+ARM A: obtained =< 14 days prior to registration: \r\n* Hemoglobin >= 10 g/dl
+ARM B: obtained =< 14 days prior to registration: \r\n* Hemoglobin >= 10 g/dl
+Hemoglobin >= 8.0 g/dL (may receive red blood cell [RBC] transfusions)
+DOSE ESCALATION COHORT: Hemoglobin ? 9 g/dL
+DOSE EXPANSION COHORT: Hemoglobin ? 9 g/dL
+Measured within 28 days prior to administration of study treatment: Hemoglobin >= 10.0 g/dL with no blood transfusion in the past 28 days
+Hemoglobin >= 9.0 g/dL (must be >= 7 days after most recent transfusion), obtained =< 14 days prior to registration
+Within 28 days prior to administration of therapy: Hemoglobin >= 10 g/dL with no blood transfusion within 28 days of initiation of therapy
+Hemoglobin >= 8 g/dL (packed red blood cells [PRBC] transfusions permitted)
+Hemoglobin >= 9 g/dL or >= 5.6 mmol/L; patients with documented marrow involvement may be transfused to this value, performed within 10 days of treatment initiation
+Obtained =< 7 days prior to registration: Hemoglobin >= 8.0 g/dL
+Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)
+Hemoglobin > 8 g/dl (use of transfusion to achieve this is acceptable)
+Hemoglobin >= 9 g/dL, unsupported by transfusions
+Transfusion dependency defined by transfusion of at least 4 units of RBC (red blood cells) within 8 weeks before Screening; pre-transfusion Hgb (hemoglobin) values must be ? 9 g/dL to be taken into account.
+Gylcated hemoglobin (HgbA1c) < 7.5%
+Hemoglobin >= 9 g/dL, without ongoing chronic blood transfusion or colony stimulating factor support to maintain normal levels; principal investigator approval is required; (limited red blood cell [RBC] transfusion is allowed for an acute change in hemoglobin)
+Hemoglobin >= 8 g/dl (may be transfused)
+Hemoglobin >= 8.0 (may transfuse)
+Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)
+Within 14 days of registration: Hemoglobin >= 9.0 g/dL
+Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)
+Hemoglobin >= 9.0 g/dL or >= 5.6 mmol/L, specimens must be collected within 10 days prior to the start of study treatment\r\n* Criteria must be met without erythropoietin dependency and without packed red blood cell (pRBC) transfusion within last 2 weeks
+Within 30 days prior to treatment initiation: Hemoglobin >= 9 g/dL or >= 5.6 mmol/L; transfusions permitted
+Hemoglobin greater than 8 g/dl (patients may receive transfusions to meet this parameter)
+Hemoglobin >= 10 g/dL (may be transfused but must be stable without clinical evidence of ongoing blood loss or hemolysis)
+Hemoglobin greater than 8 g/dL (may have received red blood cell [RBC] transfusions allowed)
+Hemoglobin >= 9.0 g/dL (obtained =< 14 days prior to registration)
+Hemoglobin >= 8 g/dL without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)
+If patient will need ribavirin in their regimen then the following inclusion:\r\n* Hemoglobin (Hg) > 12 g/dL for male\r\n* Hg > 11 g/dL for female
+Hemoglobin >= 8; transfusion is allowed
+Within 14 days of subject registration: Hemoglobin > 9 g/dL (which may be reached by transfusion)
+Within 14 days of subject registration: Hemoglobin (HB)A1c =< 8%
+Hemoglobin >= 10 g/dL (the use of transfusion or other intervention to achieve hemoglobin >= 10 g/dL is acceptable)
+Hemoglobin (Hb) at least 8 g/dL at baseline (blood transfusions are allowed during the screening period to correct Hb values less than 8 g/dL)
+Hemoglobin > 9 g/dL (which may be reached by transfusion)
+Hemoglobin >= 8 g/dl (may be after transfusion of packed red blood cells or use of erythropoiesis stimulating agents)
+Hemoglobin >= 10.0 g/dL (may receive red blood cell [RBC] transfusions)
+Hemoglobin ? 8 g/dL (80 g/L) within 14 days prior to randomization (subjects may be\n             receiving red blood cell [RBC] transfusions in accordance with institutional\n             guidelines)
+Hemoglobin >= 10.0 g/dL, measured within 28 days prior to administration of study treatment
+Hemoglobin >= 9 g/dl (per manufacturer recommendation)
+DONOR: Anemia (hemoglobin [Hb] < 11 gm/dl) or thrombocytopenia (< 100,000/ul)
+Hemoglobin >= 8.0 gm/dL (may receive packed red blood cell [PRBC] transfusions)
+Hemoglobin >= 9.0 g/dl (may be reached by transfusion)
+Hemoglobin > 8 gm/dL without transfusion and off erythropoietin for 14 days or Aranesp for 21 days
+Participants with hemoglobin level < 8 g/dL, within 21 days of initiation of protocol therapy; transfusion may be used to meet hemoglobin eligibility criteria
+Obtained within 28 days prior to registration: Hemoglobin >= 9 g/dL
+Polycythemia Vera (2 major criteria required)\r\n* Hemoglobin (Hb) > 18.5g/dl (male) or 16.5g/dl (female) or \r\n* Hematocrit (HCT) > 99 percentile reference range or \r\n* Elevated red cell mass (> 25% above mean predicted value) or \r\n* Hb > 17g/dl (male) or 15g/dl (female) if associated with a sustained rise from baseline with no apparent cause (e.g. treated iron deficiency)\r\n* Presence of JAK2V617F
+Hemoglobin >= 9 g/dL; these results must be obtained within 28 days prior to registration
+Hemoglobin < 8 g/dL within 21 days of initiation of protocol therapy; transfusion may be used to meet hemoglobin eligibility criteria
+Hemoglobin greater than or equal to 9 g/dL; patients may not have had a transfusion within 7 days of screening assessment
+Hemoglobin level at least 6.5 g/dL at Screening visit
+Hemoglobin >= 10 g/dL be obtained within 42 days prior to registration
+Hemoglobin >= 9.0 g/dl (may be reached by transfusion)
+CLINICAL/LABORATORY CRITERIA: Hemoglobin >= 9 grams/dl; these results must be obtained within 28 days prior to registration
+Performed within 14 days of patient registration: Hemoglobin > 9 g/dL(which may be reached by transfusion)
+Hemoglobin >= 9 g/dL\r\n* Blood transfusions are allowed at any time during the screening, treatment or follow-up period, according to the center recommendations
+REGISTRATION #2 - PRIOR TO CONSOLIDATION CHEMOTHERAPY: Hemoglobin >= 9.0 g/dl
+Hemoglobin >= 9.0 g/dl obtained within 28 days prior to registration
+Hematology: ANC < 1.5 x109/L; Plt < 100 x109/L Hgb < 9.0 g/dL within 7 days prior to enrollment. The use of transfusion or other intervention to achieve Hb ? 9 g/dL is acceptable.
+Hemoglobin >= 9 g/dL obtained within 28 days prior to RE-TREATMENT registration
+(A) Anemia (hemoglobin <10 g/dl or >2 g /dL below the lower limit of laboratory normal)
+Hemoglobin ? 9.0 grams/deciliter (g/dL) (can be corrected by growth factor or transfusion) and
+Hematologic: Platelets ? 100 x 10^9/L; Hemoglobin ? 9.0 g/dL; absolute neutrophil count (ANC) ? 1.5 x 10^9/L (without platelet transfusion or any growth factors within previous 7 days of the hematologic laboratory values obtained at screening visit)
+Hemoglobin greater than 8.0 g/dL (= 80 g/L or 4.9 mmol/L)
+Within 14 days prior to registration: Hemoglobin >= 9 g/dL
+Hemoglobin >= 9.0 g/dL, obtained =< 21 days prior to registration
+Must have symptomatic anemia untransfused with hemoglobin < 9.5 g/dL =< 8 weeks prior to randomization or with red blood cells (RBC) transfusion dependence (i.e., >= 2 units/month) confirmed for =< 8 weeks before randomization\r\n* NOTE: For non-transfusion dependent patients (i.e., receiving < 2 units/4 weeks x 8 weeks pre-study) who receive periodic transfusions, the mean 8 week pre-transfusion hemoglobin should be used to determine protocol eligibility and response reference\r\n* For non-transfusion dependent patients, a minimum of 2 pre-transfusion or un-transfused hemoglobin values are required
+Patients must have a serum erythropoietin level documented before randomization and =< 56 days before day 1 of study treatment; NOTE: hemoglobin must be < 9.5 g/dL at time that serum erythropoietin is drawn
+Hemoglobin >= 8 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)
+Hemoglobin ?9.0 g/dL without transfusion within the 2 weeks prior to Day 1.
+SUB-PROTOCOL AIM A: Hemoglobin >= 9.0 g/dL
+Hemoglobin >80 g/dL (without transfusion support within 7 days from start of leukapheresis)
+Hemoglobin >10.5 g/dL (without erythropoietin or blood transfusion within the last 2 weeks)
+Patients must have adequate organ and marrow function measured within 28 days prior to administration of ABT-888 as defined below:\r\n* >= 10.0 g/dL hemoglobin (Hb) with no blood transfusion in the past 28 days
+Hemoglobin (Hb) >= 9 g/dL; blood transfusion to meet the inclusion criteria will not be allowed
+Hemoglobin > 9 g/dL (International System [SI] units: 90 g/L) without transfusion support or growth factors within 10 days of starting INC280
+Hemoglobin >= 9 g/dL (prior to transfusions)
+Hemoglobin >= 9 gm/dL (may be corrected by transfusion)
+Hemoglobin >= 90 g/L (patients may be transfused to meet this criterion), obtained within 14 days prior to initiation of study treatment
+Hemoglobin ? 9 g/dL. Patients may receive red blood cells (RBC) and/or erythropoietin (EPO) and/or platelet transfusions in accordance with institutional guidelines.
+Hematologic: Platelets ? 100 x 109/L; Hemoglobin ? 9.0 g/dL; absolute neutrophil count (ANC) ? 1.5 x 10^9/L (without platelet transfusion or any granulocytic growth factors within previous 7 days of the hematologic laboratory values obtained at screening visit)
+Screening hematology values of the following: absolute neutrophil count ? 1000/?L, platelets ? 100,000/?L, hemoglobin ? 10 g/dL (without transfusion support);
+Hemoglobin ? 9 g/dL. This criterion must be met without transfusion.
+Hemoglobin >8 g/dL. Participants may be transfused to achieve this value. Elevated indirect bilirubin due to post transfusion hemolysis is allowed.
+Hemoglobin ? 9g/dl (unsupported) for 7 days
+Hemoglobin (Hgb) >= 9.0 g/dL (no red blood cell [RBC] transfusion within past 14 days)
+blood transfusion(s) prior to 1990,
+Hemoglobin >= 9 g/dL (transfusions are acceptable)
+Hemoglobin >= 9 g/dL; erythropoietin and transfusion support is permitted provided treatments are not required more than every 8 weeks; hemoglobin must be stable above or equal to 9 g/dL for at least 2 weeks prior to day 1 of study drug without blood transfusion to maintain hemoglobin level
+Hemoglobin >= 8 gm/dL (may be transfused to achieve this level), AND
+Hemoglobin >= 9.0 g/dL (SI units gm/L)
+Hemoglobin >= 8.0 g/dL obtained =< 7 days prior to registration
+Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment) (within 14 days prior to day 1 of protocol therapy)
+Hemoglobin ?8 g/dL and no red blood cell (RBC) transfusions during the prior 14 days
+Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment) (performed within 10 days of treatment initiation)
+Hemoglobin >= 9 g/dL (after transfusion, if necessary) within 4 weeks of pre-registration
+Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment), performed within 10 days of treatment initiation
+Red blood cell (RBC) transfusion dependent, defined as requiring at least 4 RBC units transfused over an 8-week period during the 16 weeks prior to Study Entry; pre-transfusion hemoglobin (Hb) should be less than or equal to 9.0 gram per deciliter (g/dL) to count towards the 4 units total
+Hemoglobin (Hb) > 9 gm/l
+Hemoglobin >= 8 gm/dl (untransfused)
+Prior to cyclophosphamide and T cell infusions: hematocrit (Hct) =< 24% or hemoglobin (Hb) =< 8 g/dL
+Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency
+Within 14 days prior to registration: hemoglobin >= 9.0 g/dL
+Hemoglobin >= 9 g/dL continuation of erythropoietin products is permitted obtained =< 7 days prior to randomization; hemoglobin must be stable >= 9 g/dL >= 14 days without blood transfusion to maintain hemoglobin level
+Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)
+Hemoglobin >= 8.0 g/dL (may be supported by erythropoietin); AND
+Hemoglobin > 9.0 without transfusion support in the past 28 days
+Hemoglobin >= 9.0 g/L, within 14 days of study registration
+Hemoglobin (Hb) >= 9 g/dL; blood transfusion to meet the inclusion criteria will not be allowed
+Hemoglobin >= 9.0 g/dL, obtained within 14 days prior to first treatment
+Hemoglobin A1c =< 9%
+Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment), should be performed within 28 days of treatment initiation, unless otherwise indicated
+Absence of anemia attributed to the plasma cell disorder*: hemoglobin > 10 g/dl or not more than 2 g/dL below the lower limit of normal\r\n* To be determined based on clinical and laboratory assessment by the primary oncologist
+Hemoglobin >= 10 g/dL (transfusions are not permissible)
+Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)
+Hemoglobin (Hb) > 9.0 g/dL within 7 days prior to enrollment; note: the use of transfusion or other intervention to achieve Hb >= 9 g/dL is acceptable (within 7 days prior to registration)
+Patient must have a hemoglobin >= 9 gm/dl (this may be achieved by transfusion if needed) obtained within 14 days before registration; if a patient receives packed red blood cell transfusion to achieve a hemoglobin level of >= 9 gm/dl, the hemoglobin level needs to be stable (no drop by more than 1 gm/dl from the post-transfusion hemoglobin level) for at least 1 week
+Within 14 days prior to the first study treatment (cycle 1, day 1): Hemoglobin >= 9.0 g/dL
+Hemoglobin >= 8.0 g/dL, performed within 28 days of treatment initiation
+Hemoglobin >= 7.0 gm/dL obtained =< 7 days prior to registration
+Anemia: hemoglobin value of > 20 g/L below the lower limit of normal, or a hemoglobin value < 100 g/L
+Hemoglobin (Hb) >= 9 g/dL without transfusion for 3 weeks
+Hemoglobin >= 8 g/dL (may receive transfusions)
+Hemoglobin > 9.0 g/dL obtained =< 14 days prior to registration
+Hemoglobin ? 8.0 g/dL (Use of erythropoietic stimulating factors and red blood cell [RBC] transfusion per institutional guidelines is allowed, however the most recent RBC transfusion may not have been done within 7 days prior to obtaining screening hemoglobin.)
+Hemoglobin >= 9 g/dL (transfusions allowed)
+Hemoglobin (Hb) >= 9 g/dL; blood transfusion to meet the inclusion criteria will not be allowed
+Participants with hemoglobin level < 8.0 g/dL, at time of screening; transfusion may not be used to meet eligibility criteria within 7 days of obtaining screening evaluation
+Hemoglobin > 9.0 g/dL (obtained =< 7 days prior to randomization)
+Hemoglobin >= 9 g/dL or >= 5.6 mmol/L, performed within 14 days prior to registration
+Within 14 days of treatment initiation: Hemoglobin >= 9 g/dL or >= 5.6 mmol/L
+Performed within 28 days of radiation therapy: Hemoglobin >= 9 g/dL or >= 5.6 mmol/L
+Hemoglobin >= 8.0 g/dl (may receive red blood cell [RBC] transfusions)
+Hemoglobin >= 9 g/dL or >= 5.6 mmol/L, performed within 28 days of treatment initiation
+Hemoglobin (Hgb) >= 9 g/dL and no red blood cell (RBC) transfusion within the past 14 days prior to study registration
+Hemoglobin >= 9.0 g/dL (hemoglobin may be supported by transfusion) obtained =<14 days prior to randomization
+Hemoglobin >= 8 g/dl (can be transfusion dependent)
+Hemoglobin >= 9.0 g/dL (not requiring transfusions within the past 2 weeks)
+Hemoglobin >= 9 g/dL OR >= 5.6 mmol/L (labs should be performed within 14 days of treatment initiation)
+Hemoglobin > 10 gm/dl; eligibility level for hemoglobin may be reached by transfusion
+Hemoglobin >= 8 g/dL (may be post-transfusion)
+Hemoglobin >=9.0 grams/decilitre(g/dL) (after transfusion if needed)
+Hemoglobin >= 8 g/dL\r\n* Transfusions and erythropoietin supplementation permitted
+Hemoglobin ? 8 g/dL (may be transfused ? 5 days)
+Hemoglobin >= 9.0 g/dL (90 g/L); previous transfusion is allowed
+Hemoglobin >= 9 g/dL (patients may be transfused to meet this requirement)
+Hemoglobin >= 9 g/dL (>= 80 g/L; may be transfused)
+Hemoglobin value >= 9 g/dL (Note: patients whose anemia has been corrected to a hemoglobin value >= 9 g/dL with blood transfusions are allowed)
+Hemoglobin (Hb) >= 9 g/dL; blood transfusion to meet the inclusion criterion will not be allowed
+Hemoglobin > 9 g/dL (80 g/L) within 30 days prior to cycle 1 day 1 (subjects may be receiving red blood cell transfusions in accordance with institutional guidelines)
+Hemoglobin value >= 9 g/dL (Note: patients whose anemia has been corrected to a hemoglobin value >= 9 g/dL with blood transfusions are allowed)
+Hemoglobin >9 g/dL (Subjects are allowed to be transfused to this level)
+Hemoglobin >= 9.0 g/dL (transfusion permitted)
+At least 4 weeks (28 days) prior to registration: Hemoglobin > 8 g/dL (which may be reached by transfusion)
+Hematocrit (Hct) =< 24% or hemoglobin (Hb) =< 8 g/dL
+Hemoglobin =< 10.0 g/dL for males and =< 9.0 g/dL for females (transfusion allowed to achieve or maintain levels)
+Hemoglobin ? 8.0 g/dL with or without transfusion support
+Hemoglobin < 8g/dL (<4.9 mmol/L; prior red blood cell [RBC] transfusion is permitted)
+Hemoglobin >= 90 gm/L
+Participants with hemoglobin level < 8.0 g/dL, at time of screening; transfusion may not be used to meet eligibility criteria within 7 days of obtaining screening evaluation
+Hemoglobin (Hg) >= 8g/dL (unsupported)
+Hemoglobin ? 8 g/dL (transfusion is permitted to fulfill this criterion)
+Hemoglobin >= 9 g/dL (5.6 mmol/L) (tested within 14 days prior to registration)\r\n* Subjects may not have had a transfusion within 7 days of screening assessment
+Hemoglobin >= 8 g/dL (80 g/L) within 14 days prior to initial treatment (subjects may be receiving red blood cell [RBC] transfusions in accordance with institutional guidelines)
+Within 30 days prior to initiation of protocol treatment: Hemoglobin >= 9.0 g/dL (after transfusion if required)
+Hemoglobin >= 8.0 g/dL with no blood transfusion in the past 28 days.
+Hemoglobin >= 8 g/dL. No transfusion or growth factor support for one week prior to labs.
+Obtained within 14 days prior to the first study treatment (cycle 1, day 1); hemoglobin ? 9.0 g/dL
+Hemoglobin > 9 g/dL (prior transfusion permitted)
+Hemoglobin >= 8 g/dL, unless if cytopenias are deemed to be due disease at discretion of clinical investigator; transfusions and growth factors are permissible
+Hemoglobin > 9 g/dL (80 g/L) within 7 days of time of consent (subjects may be receiving red blood cell transfusions in accordance with institutional guidelines)
+Hemoglobin >= 10 gm/dl; eligibility level for hemoglobin may be reached by transfusion
+Hemoglobin >= 10.0 g/dL independent of transfusion
+Hemoglobin > 9.0 g/dL (transfusion and/or erythropoiesis stimulating agents [ESA] allowed)
+Hemoglobin >= 10 gm/dl (may be reached by transfusion)
+Hemoglobin >= 8 g/dl (transfusion support allowed)
+Hemoglobin >= 9.0 g/dl (may be reached by transfusion)
+Hemoglobin >= 9 g/dL (5.6 mmol/L); subjects may not have had a transfusion within 7 days of screening assessment
+Hemoglobin > 8gm/dL (transfusions permitted)
+Hemoglobin (Hb) >= 9 mg/dl
+Hematocrit =< 28% or hemoglobin =< 9 g/dL (but may have red blood cell [RBC] transfusion)
+Hemoglobin >= 9 g/dL without need for hematopoietic growth factor or transfusion support within 30 days prior to treatment initiation
+Hemoglobin >= 9 g/dL (transfusion to this level is allowed)
+Hemoglobin >= 9 g/dL (it is acceptable to reach this through transfusion)
+Hemoglobin < 5.6 mmol/L (9 g/dL) at the screening visit (note: patients may not have received any growth factors within 7 days or blood transfusions within 28 days of the hematologic laboratory values obtained at the screening visit)
+Hemoglobin >= 9 g/dL (blood transfusion permitted to attain this value)
+Hemoglobin >= 8 g/dL (may have received packed red blood cell transfusion)
+Hemoglobin >= 9 g/dL (5.6 mmol/L); subjects may not have had a transfusion within 7 days of screening assessment
+Hemoglobin >= 9.0 g/dL not requiring transfusions within the past 2 weeks
+Measured within 28 days prior to administration of ABT-888: >= 10.0 g/dL hemoglobin (Hb) with no blood transfusion in the past 28 days
+Hemoglobin >= 8.0 g/dL (may receive red blood cell [RBC] transfusions)
+Hemoglobin >= 9 g/dL (5.6 mmol/L); subjects may not have had a transfusion within 7 days of screening assessment
+Hemoglobin >= 9.0 g/dL obtained =< 14 days prior to randomization
+Within 14 days after subjects signed the treatment consent: Hemoglobin >= 10 g/dl; patients may be transfused packed red blood cells (PRBCs) up to 1 week prior to when enrollment labs are drawn; on study, transfusions may be given as clinically indicated
+Hemoglobin >= 9 prior to biopsy
+Within 14 days prior to registration: Hemoglobin >= 10
+Hemoglobin >= 9 g/dL (>= 80 g/L; may be transfused)
+Hemoglobin >= 9 g/dL (5.6 mmol/L); subjects may not have had a transfusion within 7 days of screening assessment
+Hemoglobin >= 9 g/dl (transfusion permitted)
+Hemoglobin >= 10 gm/dl (eligibility level for hemoglobin may be reached by transfusion)
+Hemoglobin >= 8.0 g/dl with transfusion support
+Hemoglobin >= 8.0 g/dL (obtained =< 14 days prior to registration)
+Has hemoglobin <8.0g/dL. The use of transfusion with pRBC to correct anemia and meet eligibility criteria will not be allowed.
+Hemoglobin >= 9 g/dL (without transfusion within 7 days of assessment)
+Hemoglobin >= 10 g/dL (after transfusion if necessary)
+Hemoglobin >= 8.0 g/dL (without transfusion or growth factor support)
+Hemoglobin (Hb) at least 9 g/dL (or 5.69 mmol/L) at baseline (blood transfusions, hematopoietic growth factors and hematinics are not allowed during the 7 days prior to screening to correct Hb values less than 9 g/dL)
+Hemoglobin >= 9 g/dl (may transfuse packed red blood cells [PRBC] to meet parameter)
+Hemoglobin >= 9 g/dL; subjects may not have had a red blood cell (RBC) transfusion within 7 days of screening assessment
+EXPANSION COHORT ONLY: Hemoglobin >= 9 g/dL; subjects may not have had an RBC transfusion within 7 days of screening assessment
+Hemoglobin >= 8 gm/dL (can be transfused) within two weeks prior to enrollment
+Hemoglobin >= 8 g/dL; if anemia is present to the extent that the hemoglobin is < 8 g/dL, then correction by transfusion is indicated before entry into this study
+Hemoglobin: >= 8 g/dL (no transfusions within 7 days) within 30 days prior to registration
+Hemoglobin >= 9.0 g/dL (obtained within 14 days prior to the first study treatment [course 1, day 1])
+Within 8 weeks of randomization: Hemoglobin value >= 9 g/dL (Note: patients whose anemia has been corrected to a hemoglobin value >= 9 g/dL with blood transfusions are allowed)
+Hemoglobin >= 9.0 mg/dL without red blood cell transfusion =< 7 days prior to cycle 1 day 1 of therapy
+Hemoglobin >= 9.0 g/dL, obtained within 14 days prior to first treatment
+Hemoglobin ? 9 g/dL (uncorrected by RBC transfusion)
+Hemoglobin (Hgb) >= 8.5 g/dL (transfusion or erythropoietin-like substances not permitted prior to baseline evaluation)
+Hemoglobin ? 9 g/dL, (? 8 g/dL for subjects who are transfusion dependent)
+Hemoglobin > 10 gm/100ml
+Hemoglobin concentration > 8 g/dL (with or without support)
+Recipients with agnogenic myeloid metaplasia must have at least 2 of the following features:\r\n* Hemoglobin < 10 g/dl, or > 10 g/dl with transfusion dependence\r\n* WBC < 4,000 or > 30,000/mm^3 or requires cytoreductive therapy to maintain\r\n* WBC < 30,000/mm\r\n* Abnormal cytogenetics including +8, 12p-
+DONOR: Presence of sickle hemoglobin as demonstrated by appropriate testing such as hemoglobin electrophoresis
+Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)
+Hemoglobin >= 10 mg/dL (in the absence of transfusion within 24 hours prior to dosing)
+Hemoglobin ? 9 g/L (?5.6 mmol/L).
+Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)
+Hemoglobin greater than 10 g/dl (patients may be transfused to achieve this hemoglobin)
+Hemoglobin >= 9.0 g/dL (patients may be transfused to meet this criterion)
+Hemoglobin >= 8 g/dL (transfusion support allowed)
+Hemoglobin >= 9.0 mg/ml
+Hemoglobin 9.0 g/dL (transfusion to meet this criterion is permitted)
+Hemoglobin >= 8 g/dL (without platelet transfusion or myeloid growth factor support within two weeks of screening)
+Hemoglobin ?9 g/dL, without the need for transfusion in the 2 weeks prior to screening
+Hemoglobin ? 9 g/dL, without the need for transfusion in the 2 weeks prior to screening
+Anemia (hemoglobin [Hb] < 10 g/L)
+Hemoglobin (Hb) > 9 g/dL or values >= lower limit of normal (LLN) for site-specific lab
+Hemoglobin: >= 8 g/dL (may be transfused)
+Hemoglobin >= 9 gm/dL (may be transfused)
+DONOR: hemoglobin/hematocrit; 12.5-18 g/dl, 38 to 54%
+Hemoglobin >= 9.0 g/dl (transfusion and/or growth factor support allowed)
+TREATMENT: Hemoglobin greater than 8 g/dl (patients may receive transfusions to meet this parameter)
+Hemoglobin >= 9.0g/dL (without need for transfusion support within 30 days; growth factor allowed)
+Hemoglobin > 8.0 g/dl based upon complete blood count (CBC)/differential obtained within 2 weeks prior to registration on study
+Hemoglobin >= 9 g/dL unsupported by transfusions within 7 days
+RECURRENT/ PROGRESSIVE DIPG (STRATUM 1): Hemoglobin >= 8 g/dl (may receive transfusions)
+NON-PROGRESSED DIPG (STRATUM 2): Hemoglobin >= 8 g/dl (may receive transfusions)
+Hemoglobin >= 9.0 g/deciliter should be obtained with 28 days prior to randomization
+Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment) within 7 days of treatment initiation
+Within 14 days prior to first study treatment: Hemoglobin >= 9.0 g/dL
+Hemoglobin >= 8 g/dL (transfusions are permissible)
+Hemoglobin (Hb) >=10.0 gram per deciliter (g/dL) (can be corrected by growth factor or transfusion).
+Hemoglobin > 9 g/dL, +/- 7 days from date of ICF signing
+Hemoglobin >= 10 g/dL (may be post-transfusion)
+Hemoglobin >= 8.0 g/dL (may receive red blood cell [RBC] transfusions)
+Hemoglobin ? 9.0 g/dL and not requiring > 1 unit red blood cell transfusion per month; subjects receiving therapeutic erythropoietin preparations in accordance with the FDA product label are eligible to enroll;
+Hemoglobin ? 9 g/dL (with no RBC transfusions within 7 days of Screening)
+Hemoglobin < 9 g/dL (< 5.5 mmol/L; previous red blood cell transfusion is permitted)
+Hemoglobin >= 8.0 g/dL (may receive transfusions)
+Hemoglobin >= 9.0 g/dL (patients may be transfused to meet this criterion)
+Hematologic: Platelets ? 100 x 10^9/L; Hemoglobin ? 9.0 g/ dL; Absolute neutrophil count (ANC) ? 1.5 x 10^9/L (without platelet transfusion or any growth factors within previous 7 days of the hematologic laboratory values obtained at screening visit). Patients in the Group 3 lymphoma expansion may be enrolled with an ANC of ? 1.0 x 10^9 /L; Platelets ? 75 x 10^9 /L.
+Hemoglobin >= 10 g/dL (it is acceptable to reach this through transfusion)
+The hemoglobin level must be greater than 9 g/dL; low hemoglobin counts may be corrected with transfusion to achieve eligibility for study
+Performed within 10 days of treatment initiation: Hemoglobin >= 9 g/dL OR >= 5.6 mmol/L
+Hemoglobin >= 5.59 mmol/L or 9 g/dL; up to 5% deviation is tolerated; transfusions and growth factors are allowed
+Hemoglobin >= 8.0 g/dL (may receive red blood cell [RBC] transfusions)
+Hemoglobin >= 8.0 g/dL obtained at baseline (day 1 of cycle 1, before study drug administration)
+Hematologic: Absolute neutrophil count > 1.5 x 109/L, platelets > 100 x 109/L, hemoglobin ? 9 g/dL (Patients may receive erythrocyte transfusions to achieve this hemoglobin level at the discretion of the investigator. The first dose of study drug must not begin until 5 days after the erythrocyte transfusion);
+Must have adequate bone marrow and renal/hepatic function at the screening visit (?7 days preceding the lab assessment): i. ANC ? 1,500/mm3, without G-CSF ii. Platelets ? 100,000/mm3, without transfusion iii. Hemoglobin ? 9 g/dL, without transfusion support iv. AST or ALT ? 3 × ULN v. Total serum bilirubin ? 1.5 times ULN vi. Serum creatinine ? ULN vii. Potassium and magnesium levels within normal limits. If below the lower limit of normal, must have levels corrected by supplementation prior to starting study drug. viii. albumin > 3.0 g/dL
+Hemoglobin ³ 9.0 g/dL within first 2 weeks prior to first dose of MEDI0680 (AMP-514)
+Hemoglobin at least 10 g/L (transfusion is allowed to achieve hemoglobin of 10 g/L)
+Hemoglobin >= 9.0 g/dL (not requiring transfusions within the past 2 weeks)
+Hemoglobin (Hb) >= 9g/dL (women) or >= 11g/dL (men) (supportive transfusions will be allowed during induction and maintenance phases to maintain these levels)
+Hemoglobin ? 9.0 g/dL (in case of transfusion stable for ?14 days prior to treatment start)
+Hematocrit ? 25% or hemoglobin ?9 g/100 mL
+Hemoglobin >= 8 g/dL (with transfusions)
+Bone Marrow: Absolute neutrophil count ANC ? 1,500/mm3 (1.5 × 109/L); Platelets ? 100,000/mm3 (100 × 109/L); Hemoglobin ? 9.5 g/dL (1.4 mmol/L). Subjects with hemoglobin ? 9.5 g/dL (1.4 mmol/L) following transfusion are eligible;
+Hemoglobin > 9.0 g/dL (patients are allowed to receive transfused red blood cells [RBC] to achieve this level)
+Hemoglobin ?8 g/dL [transfusion permitted]
+Hemoglobin >= 8 g/dL (80 g/L) within 14 days prior to randomization (subjects may be receiving red blood cell [RBC] transfusions in accordance with institutional guidelines)
+Hemoglobin (Hb) level < 9 gm/dl
+Anemia, Hemoglobin (Hgb) ? 9.0 g/dL or ? 2 units of Red Blood Cells (RBCs) within 84 days
+Anemia (hemoglobin <11 mg/dL) or thrombocytopenia (platelets<100,000/?L).
+Hemoglobin ? 9 g/dL (transfusions are allowed)
+Hemoglobin ?8 g/dL [transfusion permitted]
+Hemoglobin >= 9 g/dl (subjects may be receiving red blood cell [RBC] transfusions in accordance with institutional guidelines)
+Hemoglobin >= 10.0 g/dL; note: this level may be reached by transfusion
+Hemoglobin (Hb) > 8 gr/dL not supported by transfusions
+Hemoglobin >= 8 g/dL, within 14 days prior to initiation of study drug
+Hemoglobin ? 8.0 g/dL within 21 days prior to randomization. Use of erythropoietic stimulating factors and red blood cell (RBC) transfusions per institutional guidelines is allowed, however most recent RBC transfusion may not have been done within 7 days prior to obtaining screening hemoglobin.
+Hemoglobin >/= 10.0 g/dL without transfusion support
+Hemoglobin >= 10 g/dL (unsupported)
+Hemoglobin (Hb) greater than or equal to 10g/dL at baseline (blood transfusions,hematopoietic growth factors and hematinics are allowed during the Prerandomization Phase to correct Hb values less than 10g/dL).
+Hemoglobin >= 9.0 g/dL not requiring transfusions within the past 2 weeks
+Hemoglobin >= 9 g/dL; subjects may not have had a transfusion within 7 days of screening assessment
+Hemoglobin ? 8 g/dL (80 g/L) within 21 days prior to randomization
+Patients must have documented hemoglobin level of 10g/dL or higher
+Hemoglobin >= 9 mg/dl (NOTE: eligibility level for hemoglobin may be reached by transfusion)
+Hemoglobin > 8 g/dl (may be transfusion dependent)
+Hemoglobin ? 8 g/dL without red blood cell transfusion within 72 hours of screening.
+Hemoglobin (Hg) >= 9.0 mg/dL
+Hemoglobin > 10 g/dL (transfusions allowed)
+Hemoglobin ? 10 g/dL, independent of transfusion or growth factor support
+Hemoglobin > 8 mg/dL without need for hematopoetic growth factor or transfusion support
+Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)
+Hemoglobin greater than 8g/dl (patients may receive transfusions to meet this parameter)
+Hemoglobin >= 9 g/dL without transfusion within 1 week preceding study drug administration
+Hemoglobin < 9.0 gm/dL (SI units gm/L)
+Hemoglobin >= 9.0 g/dL (SI units 90 g/L)
+Hemoglobin > 9.0 g/dL (no transfusion permitted within 1 week)
+Hemoglobin (Hb) >= 9 g/dL; blood transfusion to meet the inclusion criteria will not be allowed
+Hemoglobin >= 9 g/dL (>= 80 g/L; may be transfused)
+Hemoglobin > 7.0 g/dL unless due to marrow involvement by lymphoma
+Anticipating surgery, history of hypothyroidism, profound anemia (hemoglobin level of < 10 g/dL =< 28 days prior to registration), or clinical depression per physician discretion
+Hemoglobin >= 10 g/dL (allowing transfusion or other intervention to achieve this minimum hemoglobin)
+Hemoglobin > 8 g/dL (international system [SI] units: 80 g/L); patients may receive erythrocyte transfusions to achieve this hemoglobin level at the discretion of the investigator; initial treatment must not begin earlier than the day after the erythrocyte transfusion
+Hemoglobin level of at least 10 g/dL (transfusion is allowed to achieve hemoglobin level of at least 10 g/dL).
+Performed within 10 days of treatment initiation: Hemoglobin >= 9 g/dL or >= 5.6 mmol/L
+Hemoglobin >= 9 g/dL within 28 days prior to registration
+Hemoglobin ?10.0 grams per deciliter (g/dL) (can be corrected by growth factor or transfusion prior to first dose of study drug);
+Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment) (performed within 10 days of treatment initiation)
+Hemoglobin >= 9 g/dL (patients may be transfused to meet this criterion) (obtained within 28 days prior to the first study treatment)
+Hemoglobin > 8 g/L within 1 week of enrollment in the study
+Obtained within 14 days prior to initiation of treatment: Hemoglobin >= 8.0 g/ dL
+Hemoglobin of >=10 g/dl within 2 weeks of enrollment; if the patient has not had blood drawn for a hemoglobin level in the past two weeks, one will be done to determine the eligibility
+Hemoglobin >= 11.0 g/dL obtained =< 180 days prior to registration
+Significant anemia with hemoglobin level less than 7 g/dL or a hematocrit less than 21%
+Hemoglobin >= 9.0 gm/dL (transfusion permitted)
+Hemoglobin of >= 10 g/dl within 2 weeks of enrollment; if the patient has not had blood drawn for a hemoglobin level in the past two weeks, one will be done to determine the eligibility
+Hemoglobin >= 9.0 g/dL, obtained within 14 days of the first dose of study drug
+Screening blood counts of the following: Absolute neutrophil count ? 1000/?L, Platelets ? 75,000/?L, Hemoglobin ? 8 g/dL (with transfusion support);
+Hemoglobin >= 10 g/dL (for Arm L pembrolizumab and Arm M nivolumab and expansion cohorts for all arms, hemoglobin >= 9 g/dL
+Hemoglobin (Hgb) >= 8 g/dL and no red blood cell (RBC) transfusion within the past 21 days prior to study registration
+Have a hemoglobin level of >= 10 g/dL within 2 weeks of enrollment
+Hemoglobin level of >= 8 g/dL within 2 weeks of enrollment; if the patient has not had blood drawn for a hemoglobin level in the previous two weeks, one will be performed to determine eligibility; patients with a hemoglobin level < 9g/dL will be referred for treatment of anemia
+Hemoglobin level less than or equal to 11.0 g/dL as assessed by the local laboratory; sample obtained within 7 days prior to randomization (retest in screening is acceptable).
+Hemoglobin > 8 mg/dl; Physician can maintain a patient's hemoglobin with the use of erythropoietin or transfusions (prophylactic use of G-CSF [filgrastim] is not permitted)
+Hemoglobin > 11.0 g/dL within 28 days prior to registration
+Hemoglobin >= 8 g/dL obtained =< 30 days prior to registration
+Hemoglobin > 8.0 g/dL; red blood cell transfusions to help patients meet eligibility criteria are not allowed within 3 days before study enrollment
+Hemoglobin >= 10 g/dL or hematocrit >= 30%
+Patients must have hemoglobin level >= 11gm/dl (age adjusted if appropriate) provided by the reference laboratory performing the test
+Hemoglobin >= 10 g/dL or hematocrit >= 30% obtained =< 45 days prior to randomization
+worsening hemoglobin should be ? 1.5 g/dL decrease from preinjectable HMA (HYPOMETHYLATING AGENT) baseline value in subjects not receiving RBC (RED BLOOD CELL) transfusions
+Hemoglobin >= 9 g/dL, obtained within 14 days prior to treatment start
+Measured within 28 days prior to administration of study treatment: Hemoglobin >= 10.0 g/dL
+Hemoglobin >= 9 g/dL (transfusions and/or erythropoietin are permitted)
+Hemoglobin ? 10 g/dL without need for hematopoietic growth factor or transfusion support
+Anemia, defined as hemoglobin <10 gram per deciliter (g/dL) or >2 g/dL below lower limit of normal or both; transfusion support or concurrent treatment with erythropoietin stimulating agents is not permitted
+Within 14 days prior to study entry: Hemoglobin > 9 gm/dl
+Hemoglobin >= 9 g/dL or >= 5.6 mmol/L, performed within 10 days of treatment initiation
+Hemoglobin ? 9.0 g/dL (in the absence of red blood cell transfusions in the prior 14 days)
+Hemoglobin >= 9 g/dL (5.6 mmol/L) (evaluated within 28 days of randomization); subjects may not have had a transfusion within 7 days of screening assessment
+Hemoglobin >= 90 g/L independent of transfusion
+Hemoglobin >= 8.0 gm/dL (may receive packed red blood cell [pRBC] transfusions)
+Hemoglobin >= 8.5 g/dL without transfusion support > 7 days prior to registration
+Hemoglobin ?9 g/dL(without transfusion support)
+Hemoglobin >= 9.0 g/dL\r\n* Patients may be transfused or receive erythropoietic treatment to meet this criterion
+Hemoglobin >= 7g/dL (transfusion permitted)
+Hemoglobin >= 9.0 g/dL (within 14 days of study registration)
+Hemoglobin >= 9.0 g/dL (may receive red blood cell [RBC] transfusions)
+Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin dependency (=< 7 days prior to registration), obtained =< 30 days prior to registration
+Hemoglobin >= 8.5 g/dL or >= 5.6 mmol/L, performed within 10 days of treatment initiation
+Hemoglobin ?9.0 g/dL (may have been transfused)
+Hemoglobin >= 10 gm/dL, performed within 28 days prior to registration
+Eligibility level for hemoglobin may be reached by transfusion
+Hemoglobin A1C > 8.5%
+Hemoglobin > 5.6 mmol/L (9 g/dL) at the screening visit
+Positive Hemoglobin-Solubility (e.g., SickleDex™ or equivalent) test.
+Hemoglobin <10 g/dL (may be determined following transfusion)
+Absolute neutrophils count (ANC) ? 1.5 x 10E9/L, platelets ? 100 x 10E9/L, hemoglobin > 9 g/dL (without transfusion or erythropoiesis stimulating agents dependency).
+Hemoglobin ?9 g/dL (?90 g/L) Note that transfusions are allowed to meet the required hemoglobin level
+Patients must have >= 10.0 g/dL hemoglobin (Hb) and no blood transfusion in the past 28 days to receive veliparib
+Hemoglobin >= 10 g/dL (acceptable to reach this via transfusion)
+Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)
+Hemoglobin >= 9.0 g/dL, performed within 10 days of protocol enrollment
+Hemoglobin >= 10 g/dL (acceptable to reach this via transfusion)